Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions. Its news flow centers on the progress of its lead investigational product, laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors.
On this page, readers can follow LGVN news related to key clinical programs in hypoplastic left heart syndrome (HLHS), mild Alzheimer’s disease, pediatric dilated cardiomyopathy (DCM), and aging-related frailty. Company announcements highlight milestones such as pivotal Phase 2b trial enrollment in HLHS (ELPIS II), Phase 2a data in Alzheimer’s disease from the CLEAR MIND study, and regulatory interactions including FDA designations like Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT).
Longeveron’s news also covers intellectual property developments, including U.S. and Canadian patents for the use of its proprietary mesenchymal stem cells in aging-related frailty, non-ischemic dilated cardiomyopathy, and female sexual dysfunction. Scientific and medical conference activity, such as poster presentations at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and participation in cardiovascular clinical trial forums, provides additional insight into how the company positions laromestrocel within neurodegenerative and cardiovascular research.
Investors and observers can use this LGVN news feed to track clinical trial updates, patent grants, financing transactions disclosed in press releases, and other corporate developments that Longeveron reports through GlobeNewswire and SEC-related communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Longeveron Inc. (NASDAQ: LGVN) has commenced its Phase 2 clinical trial for Lomecel-B™ in Japan, targeting Aging-Related Frailty in the elderly population. The trial aims to enroll 45 patients and primarily focuses on assessing the safety of Lomecel-B™. Longeveron anticipates that the data collected might support limited approval under Japan's Act on the Safety of Regenerative Medicine (ASRM). The study builds on positive results from a previous U.S. trial, where patients experienced significant improvements in mobility. The trial will be conducted in collaboration with prominent medical institutions in Japan, addressing a critical need in a country with a significant aging population.
Longeveron Inc. (NASDAQ: LGVN) reported its financial results for Q4 and full year 2022, highlighting a net loss of $4.5 million in Q4, compared to $4.1 million in Q4 2021, and a total loss of $18.8 million for 2022 versus $17.0 million in 2021. Revenue for Q4 2022 was $0.1 million, down from $0.2 million in Q4 2021, largely due to fewer clinical trial participants. On a positive note, the company successfully published ELPIS I trial results in the European Heart Journal Open and initiated Phase 2 studies for Lomecel-BTM targeting aging-related frailty in Japan. They anticipate existing cash will cover expenses into H1 2024.
Longeveron Inc. (NASDAQ: LGVN) is set to release its fourth quarter and full year 2022 financial results on March 10, 2023, before U.S. markets open. A conference call will follow at 8:30 a.m. ET to discuss these results and a corporate update. The company, focused on regenerative medicines, is advancing its investigational product Lomecel-B™ for conditions including hypoplastic left heart syndrome, Alzheimer’s Disease, and Aging-Related Frailty.
For more details, investors can access the audio webcast on the company’s website.
Longeveron Inc. (NASDAQ: LGVN) has announced the appointment of Wa’el Hashad as Chief Executive Officer, effective March 1, 2023. With over 35 years of experience in drug approval, mergers, and business development, Hashad previously held executive positions at Avanir, Amgen, and Eli Lilly. His leadership is expected to drive growth across Longeveron's clinical programs focused on Alzheimer’s Disease, Aging-Related Frailty, and hypoplastic left heart syndrome. The company’s lead product, Lomecel-B™, is advancing through clinical trials, showcasing potential therapeutic benefits in regenerative medicine.
Longeveron Inc. (NASDAQ: LGVN) announced the publication of results from its ELPIS I trial for Lomecel-BTM targeting hypoplastic left heart syndrome (HLHS) in the European Heart Journal Open. The Phase 1b study included 10 infants who underwent the Glenn Procedure. Key findings revealed:
- No adverse safety events reported over one year.
- All patients were alive and transplant-free, maintaining expected growth.
- Improved cardiac function indicators noted.
- Evidence of Lomecel-BTM persistence in a subset of patients.
Longeveron is enrolling for the ELPIS II trial, further evaluating Lomecel-BTM's effectiveness, receiving support from the National Heart, Lung, and Blood Institute.